439 related articles for article (PubMed ID: 31487005)
1. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
[TBL] [Abstract][Full Text] [Related]
2. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
3. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China.
Hu Y; Ye Y; Ye L; Wang X; Yu H
Medicine (Baltimore); 2019 Aug; 98(32):e16683. PubMed ID: 31393369
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study.
Wirth S; Zhang H; Hardikar W; Schwarz KB; Sokal E; Yang W; Fan H; Morozov V; Mao Q; Deng H; Huang Y; Yang L; Frey N; Nasmyth-Miller C; Pavlovic V; Wat C
Hepatology; 2018 Nov; 68(5):1681-1694. PubMed ID: 29689122
[TBL] [Abstract][Full Text] [Related]
6. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
7. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
[No Abstract] [Full Text] [Related]
9. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.
Liu Y; Li H; Yan X; Wei J
J Viral Hepat; 2019 Jul; 26 Suppl 1():69-76. PubMed ID: 31380585
[TBL] [Abstract][Full Text] [Related]
11. An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study.
Chon YE; Kim DJ; Kim SG; Kim IH; Bae SH; Hwang SG; Heo J; Jang JW; Lee BS; Kim HJ; Jun DW; Kim KM; Chung WJ; Choi MS; Jang JY; Yim HJ; Tak WY; Yoon KT; Park JY; Han KH; Suk KT; Lee HW; Jang BK; Ahn SH
Medicine (Baltimore); 2016 Apr; 95(14):e3026. PubMed ID: 27057828
[TBL] [Abstract][Full Text] [Related]
12. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
[No Abstract] [Full Text] [Related]
13. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
15. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
[TBL] [Abstract][Full Text] [Related]
16. Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.
Zhou P; Yang F; Wang J; Mao R; Qi X; Huang Y; Zhang J
Medicine (Baltimore); 2015 May; 94(17):e730. PubMed ID: 25929904
[TBL] [Abstract][Full Text] [Related]
17. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
Sun J; Ding H; Chen G; Wang G; Wei L; Zhang J; Xie Q; Wan M; Tang H; Chen S; Gao Z; Wang Y; Zhang D; Huang W; Sheng J; Ning Q; Yang D; Lu J; Pan C; Yang Y; Wang J; Sun C; Wang Q; Hou J
BMC Gastroenterol; 2019 May; 19(1):65. PubMed ID: 31046700
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
Wang YD; Zhao CY; Wang W; Shen C; Lu HZ; Zhang L; Yu WY; Zhou JY; Yan WZ
Hepatogastroenterology; 2012 May; 59(115):680-6. PubMed ID: 22441104
[TBL] [Abstract][Full Text] [Related]
19. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B.
Fan H; Lin L; Jia S; Xie M; Luo C; Tan X; Ying R; Guan Y; Li F
J Viral Hepat; 2019 Jul; 26 Suppl 1():77-84. PubMed ID: 31380586
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]